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A recent major cluster randomized trial of screening, active disease treatment, and mass isoniazid preventive
therapy for 9 months during 2006–2011 among South African gold miners showed reduced individual-level tuber-
culosis incidence but no detectable population-level impact. We fitted a dynamic mathematical model to trial data
and explored 1) factors contributing to the lack of population-level impact, 2) the best-achievable impact if all imple-
mentation characteristics were increased to the highest level achieved during the trial (“optimized intervention”), and
3) how tuberculosis might be better controlled with additional interventions (improving diagnostics, reducing treat-
ment delay, providing isoniazid preventive therapy continuously to human immunodeficiency virus–positive people,
or scaling up antiretroviral treatment coverage) individually and in combination. We found the following: 1) The model
suggests that a small proportion of latent infections among human immunodeficiency virus–positive people were
cured, which could have been a key factor explaining the lack of detectable population-level impact. 2) The optimized
implementation increased impact by only 10%. 3) Implementing additional interventions individually and in combina-
tion led to up to 30% and 75% reductions, respectively, in tuberculosis incidence after 10 years. Tuberculosis control
requires a combination prevention approach, including health systems strengthening to minimize treatment delay, im-
proving diagnostics, increased antiretroviral treatment coverage, and effective preventive treatment regimens.
mass community-wide isoniazid preventive therapy; mathematical model; tuberculosis
Abbreviations: ART, antiretroviral treatment; CI, confidence interval; HIV, human immunodeficiency virus; IPT, isoniazid preventive
therapy.
South Africa experienced the highest tuberculosis incidence
globally (800–1,200 per 100,000) in 2011 (1), with extremely
high notiﬁcation rates among gold miners (3,000 per 100,000
in 2008) (2). Following the success of mass community-wide
isoniazid preventive therapy (IPT) in Alaska during the 1950s
(3), researchers undertook a cluster randomized trial (Thibela
TB) of mass tuberculosis screening followed by IPT in South
African gold mines (4). The intervention greatly reduced
individual-level incidence but had no detectable population-
level impact (5): Miners experienced >60% (95% conﬁdence
interval (CI): 25, 82) protection while taking IPT, but the rel-
ative incidence rate in intervention comparedwith control clus-
ters was 1.04 (95% CI: 0.73, 1.48) during the year after the
intervention stopped.
Several factors, including suboptimal IPT uptake and re-
tention, a high annual risk of infection with Mycobacterium
tuberculosis, and population mobility may have helped to
reduce the population-level impact (5), but their relative im-
portance is unclear. Because isoniazid targets actively repli-
cating rather than dormant bacilli (6), the lack of impact may
be partly attributable to IPT’s curing a low proportion of la-
tent infections, a possibility which was not appreciated at the
study initiation. Understanding the trial’s ﬁndings and inter-
ventions that might control tuberculosis is important, given
the extraordinarily high incidence in gold mines and rele-
vance for other high incidence settings.
Here, we ﬁtted a mathematical model to trial data and ex-
plored 1) factors contributing to the lack of population-level
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impact, including the proportion of infections that were cured
by IPT; 2) the best-achievable intervention impact if all im-
plementation characteristics (e.g., IPT uptake, retention) were
increased to the highest level achieved during the trial (“opti-
mized intervention”); and 3) how tuberculosis might be better
controlled, by estimating the impact of additional interventions
(improving sensitivity and screening by using new diagnostics,
such as Xpert MTB/RIF (Cepheid, Inc., Sunnyvale, Califor-
nia), reducing treatment delay, providing IPT continuously,
and/or scaling up antiretroviral treatment (ART) coverage)
both individually and simultaneously.
METHODS
The Thibela TB cluster randomized trial
Thibela TB was a cluster randomized trial in sites belonging
to 3 South African gold mining companies (4) comprising 8
intervention and 7 control clusters, including all miners at par-
ticipatingmine shafts andassociatedhostel residences.Clusters,
stratiﬁed into 2 groups (low and high tuberculosis notiﬁcations)
using data from 2004, were randomized to the intervention or
standard of care, balancing for company, province, and work-
force size. Trial impact calculations accounted for between-site
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Figure 1. Schematic of the time course of the Thibela TB randomized controlled trial among South African gold miners, 2006–2011. TB,
tuberculosis.
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Figure 2. General structure of the dynamic transmission model for an intervention cluster in the Thibela TB randomized controlled trial among
South African gold miners, 2006–2011. Because of high levels of transmission in the miners, all gold miners were assumed to have been infected
at least once in their lifetime, which accounts for the absence of an uninfected compartment. The dashed lines reflect activities relating to case
finding or isoniazid preventive therapy. The arrows out of the compartments, which have no destination, reflect out-migration or death. The small
arrows into the compartments, which do not start from any destination, reflect in-migration. The shaded boxes reflect peoplewho are taking IPT. IPT,
isoniazid preventive therapy; s−c+, smear-negative, culture-positive; s+c+, smear-positive, culture-positive; TB, tuberculosis.
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heterogeneity. Consenting miners in intervention clusters were
offered tuberculosis screening, active cases were referred for
treatment, and those without active tuberculosis or contraindi-
cations were offered 9 months of isoniazid (300 mg daily).
The primary outcome was “tuberculosis incidence” in all
clusters, measured during the “primary outcomemeasurement”
period, lasting 12 months after the last person completed IPT
in each cluster (Figure 1), with cases mainly ascertained from
treatment records. Tuberculosis prevalence was measured by
using culture conﬁrmation among systematically sampled em-
ployees at the study’s end.
Description of the model
Overview. We developed an age-structured deterministic
compartmental model (Figure 2) describing M. tuberculosis
transmission dynamics for each intervention cluster and its
control, matching identically, except for the intervention.
The model considers culture-positive tuberculosis (“active
disease”), extending previous work (7, 8). Cluster populations
comprise 4 age strata (<30, 30–39, 40–49, and≥50 years) be-
cause of age-dependent population mobility and 2 human
immunodeﬁciency virus (HIV) strata (HIV-positive or HIV-
negative). Model output is aggregated into 2 age strata (<40
and ≥40 years) or all ages, given insufﬁcient data to further
stratify the incidence and prevalence. Clusters are considered
independent, because little movement occurred between in-
tervention and control arms.
Multiple competing hypotheses exist for why the trial de-
tected no population-level impact, including suboptimal IPT
uptake and/or retention or high population mobility (5). To
robustly explore this question, we included in the model all
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1 3 6 1 3 6
A
B
C
0.00
0.05
0.10
0.15
1 2 3 4 5 6 7 8
Baseline
Final
Pr
op
or
tio
n 
Ev
er
 T
ak
en
 A
RT
Cluster
Pr
op
or
tio
n 
No
t S
ta
rte
d 
TB
 T
re
at
m
en
t
Time Since Detection, months
A) B)
C)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
1 2 3 4 5 6 7 8
In-Migration
Out-Migration
Cluster 
%
 M
ig
ra
tio
n 
pe
r M
on
th
Smear-Negative Smear-Positive
Company
Figure 3. Some of the key data used to parameterize the model describing the Thibela TB randomized controlled trial among South African gold
miners, 2006–2011. A) Proportion of miners in the baseline and final prevalence surveys that reported ever taking ART; B) proportion of smear-
positive and smear-negative miners who had not started TB treatment at different times since detection, according to mining company; C) monthly
rates of in- and out-migration. Bars (in part A), 95% confidence interval. ART, antiretroviral therapy; TB, tuberculosis.
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Table 1. Summary of the Parameter Values Used in the Base-Case and the Ranges Explored in Sampling Parameter Combinations When
Modeling a Cluster Randomized Trial of Mass Tuberculosis Screening Known as “Thibela TB,” 2006–2011
Definition Symbola Base-Case Valueb Rangeb,c Commentb
Transmission
Effective contact rate (average number
of individuals effectively contacted
by each person per unit of time)
ce Adjusted to give an annual risk
of infection averaged across
clusters of 20%/year before
the start of the intervention
5–25/year No available data
Force of infection that is attributable to
contact with the outside community
λo 0.29%/year Fixed Based on report by Wood et al. (31)
d
Infectiousness of sm− TB cases
compared with that of sm+ cases
f 22% Fixed Based on report by Behr et al. (32)
Disease Onset
Rate of onset of reactivation disease
for HIV− miners without
radiologically confirmed silicosis
dn,z−,a,h− Estimated 0.0001–0.014/year Based on reports by Vynnycky and
Fine (7), Sutherland et al. (33), Clark
and Vynnycky (34), and Vynnycky
et al. (35). The upper limit was set to
ensure biological plausibility with the
rate of disease following reinfection.
Rate of onset of (exogenous) disease
in the first year after reinfection
dx,z−,a,h− (0) Estimated 0.01–0.11/year Based on reports by Vynnycky and
Fine (7), Sutherland et al. (33), Clark
and Vynnycky (34), and Vynnycky
et al. (35).
Proportion of miners of age a that have
radiologically confirmed silicosis
psi,a Varies by age and between
clusters: ≤1% (<40 years of
age); 2%–10% (≥40 years
of age)
Fixed Based on baseline prevalence surveyd,e
Relative risk of developing TB among
miners with radiologically confirmed
silicosis, compared with that among
miners without radiologically
confirmed silicosis
ρsi,h HIV−: 2.6 1–6.5 Based on report by Corbett et al. (36). For
biological plausibility, the selected
value for the relative risk for HIV+ was
higher than that for HIV−.
HIV+: 4.1 2.4–7.1
Rate at which sm− cases become
sm+
os+,h HIV−: 0.6%/week 0.3%–0.9%/week Based on data from the report
by Corbett et al. (37)d,fHIV+: 1.78%/week 0.89%–2.7%/week
HIV and ART
HIV prevalence in the workforce h+ 0.3 0.2–0.45 Based on the report by Lewis et al. (38)
ART coverage among miners with a
CD4 count of <200 cells/mL at time t
gART,<200(t ) Varies between clusters.
Increases from 0 in 2003 to
50%–100% by 2008
Fixed Calculated from observed data. Refer
to Figure 3Ad,g
Protection provided by ART against
TB disease among those not on IPT
TTz−,ART+ 65% 48%–83% Based on the report by Suthar et al. (39)d,h
Factor by which the rate of disease
onset among those with a CD4+ cell
count in the range ci− ci+1 cells/µL
differs from that among HIV−
individuals
ρh;ciciþ1 CD4 <200: 17 8.5–25.5 Consistent with estimates in the report by
Williams et al. (40). The value for those
with a CD4 count of <200 cells/mL was
constrained to be at least as high as
that for miners with a CD4 count of
≥200 cells/mL
CD4 ≥200: 6 2.9–8.8
Proportion of HIV+ miners who have a
CD4+ count in the range ci− ci+1
ph;ciciþ1 CD4 <200: 0.25 Fixed Consistent with data in reports byWlliams
et al. (40, 41)dCD4 ≥200: 0.75
Case Detection
Proportion of new employees
with TB disease joining the
workforce that are detected
(“found”)
pin,f,s sm−: company A, 14%;
companies B/C: 1.4%
sm−: 0.7%–20% Calculated by using the sensitivity of
radiographs, proportion of miners
followed up, and the sensitivity of the
method for subsequent follow-up
(culture for company A; smear
for company B/C)b,i
sm+ (both companies): 25% sm+: 12.5%–37.5%
Rate at which cases with smear-status
s are detected (found) through the
routine medical examination
rf,s,h,y Company A: sm−, 0.22%/
week; sm+, 0.42%/week.
Company B/C: sm−, 0.02%/
week; sm+, 0.42%/week
Company A: sm−,
0.1%–0.3%/week;
sm+, 0.2%–0.42%/
week.
Company B: sm−,
0.01%–0.3%/week;
sm+, 0.2%–0.42%/
week
Calculated by using the sensitivity of
radiographs, proportion of miners
followed up, and the sensitivity of the
method for subsequent follow-up
(culture for company A; smear
for company B/C)b,i
Rate at which sm+ cases are detected
(found) through passive
presentation to the health services
rf,s+,h,p HIV+: 13%/week 6%–19%/week Calculated by using data from
the report by Corbett et al. (37)b,iHIV−: 1.6%/week 0.7%–2.3%/week
Rate at which sm− cases are detected
(found) through passive
presentation to the health services
rf,s−,h,p Company A: HIV−, 0.4%/
week; HIV+, 1.2%/week.
Company B/C: HIV−, 0.6%/
week; HIV+, 1.4%/week
All companies: HIV−,
0.2%–0.9%/week;
HIV+, 0.6%–2.2%/
week
Calculated by using data from
the report by Corbett et al. (37)b,i
Table continues
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known factors (age, HIV, silicosis, ART, in- and out-migration,
case detection, initial loss to follow-up after detection, treatment
delay, IPT uptake, and retention), at levels supported by detailed
data collected during the study or by mine health services (Fig-
ure 3;Web Figure 1 (available at http://aje.oxfordjournals.org/)).
Parameters (Table 1) were also drawn from publications or
estimated by ﬁtting model predictions to trial outcomes. Web
Appendixes 1 and 2, Web Tables 1–7, and Web Figures 1–7
provide further details, including the model equations.
General structure. All miners are infected in the model,
joining the workforce recently reinfected (<2 years previ-
ously), with active disease (some of whom are detected
on recruitment) or latent infection, consistent with miners
transferring between mines or, because of much ongoing
transmission (9, 10), being recently reinfected. Miners whose
most recent (re)infection occurred >2 years previously are
considered to be latently infected. Miners leave the cluster
through death or out-migration.
Latently infected miners can develop smear-negative,
culture-positive disease through reactivation or following
reinfection at estimated rates (see below), depending on
the HIV and (radiologically conﬁrmed) silicosis prevalence,
CD4 count distributions, and ART coverage, after which they
can become smear-positive. Smear status determines their
Table 1. Continued
Definition Symbola Base-Case Valueb Rangeb,c Commentb
Treatment
Rate at which TB cases with smear
status s who have been detected
(found) for duration sf start
TB treatment
Ts(sf) Refer to Figure 3B Fixed Based on observed data;
depends on mining companyd,j
Duration of TB (disease) treatment Tτmax 6 months Fixed Based on observed data. Note that in
reality, cases who have previously
experienced TB and cases with
multiple drug resistance are treated
for 8 months and 2 years,
respectively. However, such cases
make up a small proportion of all TB
cases (10% and 2%–2.5%,
respectively, based on observed
data in the report by van Halsema
et al. (2))
Intervention
Rate at which individuals of age a
start IPT
iz+,a(t ) Varies between clusters,
with the peak proportion
on IPT reaching
between 10% and 70%k
Fixed Based on observed data. Differs
between clusters and changes
over timed,k,l
Rate at which individuals of age a
stop taking IPT
iz−,a(t ) Varies between clusters
with the peak proportion
on IPT reaching
between 10% and 70%k
Fixed Based on observed data. Differs
between clusters and changes
over timed,k,l
Rate at which cases are detected
through the screening carried out
on recruitment into Thibela TB
q(t ) Varies between clusters Fixed Based on observed data. Differs
between clusters and changes
over timed
Protection against disease
provided by IPT for those not
on ART
TTd,z+,ART− 63% 25%–81% Based on the analyses of
individual-level data in Thibela TB in
the report by Churchyard et al. (5)
Protection against disease
provided by IPT for those on ART
TTd,z+,ART+ 82.5% 41%–83% Calculated by assuming that IPT
provides an additional 50%
protection to that provided by ART.
Consistent with reports by
Samandan et al. (13), Rangaka
et al. (42), and Golub et al. (43, 44)
Proportion of infections that are
cured (i.e., so that reactivation
cannot occur) as a result of
6 months of IPT
pzc ,h 100% for IPT assumption 1 0%–100% For biological plausibility, the values
for HIV− were constrained to be at
least as high as those for HIV+.
Estimated (IPT
assumptions 2 and 3)
0%–100%
Protection provided against
reinfection for individuals while
they are on IPT
zr,h 100% for IPTassumptions 1
and 2
0%–100% No available data
Estimated (IPT
assumption 3)
0%–100%
Minimumduration of IPT required in
order to cure infection
Tzmin 6 months Fixed Consistent with the report by
Comstock (14)
Maximum duration of IPT Tzmax 9 months Fixed Determined by Thibela TB
Table continues
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infectiousness. The annual risk of infection, depending on the
contact rate among miners and nonminers and the prevalence
of infectious individuals, changes with the intervention and is
cluster, speciﬁc. Cases can die or be detected through self-
presenting to mine health services or routine medical exam-
inations. After detection, cases can become lost to follow-up,
die, or be treated and recover; disease occurs subsequently
only after reinfection.
Once Thibela TB starts, those latently infected, reinfected,
or recovered take IPT for≤9months at cluster-speciﬁc uptake
and retention rates, and cases are detected through screening
on study recruitment. The assumed protection (63%) dur-
ing IPT comes from individual-level estimates (5), with in-
creased protection while also taking ART. Scenarios for the
proportion of infections that are cleared with 6 months of IPT
are described below.
The impact of the intervention. The impact of the interven-
tion on the “measured” tuberculosis incidence (the percentage
difference in the measured incidence between intervention
and control arms) during the primary outcome measurement
period and tuberculosis prevalence at the studyend (Figure1)
was calculated for each cluster and averaged across clusters.
Objective 1. Exploring factors contributing to the lack of
population-level impact. After inclusion of all known factors
and data (age, HIV, silicosis, ART, population mobility, case
detection, initial loss to follow-up after detection, treatment
delay, and IPT uptake and retention), the model has several
unknown parameters: the rates of disease onset through reac-
tivation and following reinfection and the proportion of in-
fections that are cured by IPT.
Because isoniazid targets actively replicating rather than
dormant bacilli (6), IPT may not cure all infections. HIV-
negative participants in preventive therapy trials typically ex-
perienced low tuberculosis incidence many years thereafter
(11), suggesting cure of latent infections; those HIV-positive
participants in presumed high-transmission settings experi-
enced high disease incidence soon after stopping IPT (12,
13), suggesting that their infections were not cured or that re-
infection occurred during IPT, with quick disease progres-
sion. When Thibela TB was planned, 6 months of IPT was
Table 1. Continued
Definition Symbola Base-Case Valueb Rangeb,c Commentb
Mortality and Migration
Average mortality rate among TB
cases before they start TB treatment
μs,h,tr− HIV−: sm−, 0.2%/month;
sm+, 1%/month.
HIV+ (both sm+ and
sm−): 5%/month
HIV–: sm−, 0.1%–0.3%/
month; sm+: 0.5%–
1.5%/month.
HIV+ (both sm+ and
sm−): 2.5%–7.5%/
month
Consistent with the report by Tiemersma
et al. (45)d
Averagemortality rate among TB cases
while they are on TB treatment
μh,tr+ HIV−: 0.13%/month; HIV+:
1.3%/month
HIV−: 0.06%–0.19%/
month; HIV+: 0.6%–
1.9%/month
Consistent with the report by Churchyard
et al. (46)
Average rate at which miners who are
not on TB treatment leave the
workforce because of out-migration
or non-TB-related death
mtr−,a Varies by age between
clusters: 2%–4%/month
(<30 years); 1%–2%/month
(≥30 years)
Fixed Based on human resources datad,m
Average rate at which miners who are
on TB treatment leave theworkforce
because of out-migration or
non-TB-related death
mtr+ Varies between clusters in the
range of 2%–7%/month
Fixed Based on human resources datad,m
Factor by which the prevalence of
TB among new mining employees
differs from that in the final
prevalence survey (after
adjustment for the
observed impact)
pin 1.0 0.3–1.5 No data available
Abbreviations: ART, antiretroviral therapy; HIV− and HIV+, human immunodeficiency virus-negative and -positive, respectively; IPT, isoniazid preventive
therapy; sm− and sm+, smear-negative and smear-positive, respectively; TB, tuberculosis.
a Several of the symbols have subscripts h, z−, z+, or a. h refers to HIV status (which can be positive or negative); z− and z+ refer to those not on IPT and on
IPT, respectively; a refers to the age group.
b The 3 mining companies are denoted by “A,” “B,” and “C.”
c The parameters were sampled from the uniform distribution. Unless otherwise stated, the base-case values and ranges are identical for each cluster. The
upper and lower limits of the ranges were taken to be 50% and −50% of the base-case value, unless confidence limits were available or the values were
constrained for consistency with other parameter values.
d Web Appendix 2.
e Web Figure 2.
f Web Figure 3.
g Web Figure 4.
h Web Table 2.
i Web Table 3.
j Web Tables 4 and 5.
k Web Figure 1.
l Web Figures 5 and 6.
m Web Figure 7.
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considered sufﬁcient (14), although 9 months was chosen,
compromising between recommendations for HIV-infected
people (6 months) or silicotics (12 months) (4). We explored
3 HIV-speciﬁc IPT assumptions:
Assumption 1 (100% cure, 100% protection). Six months
of IPT cures all infections and reinfection cannot occur
during IPT.
Assumption 2 (estimated percentage cured, 100% protec-
tion). Sixmonths of IPT can cure <100%of infections, but
reinfection cannot occur during IPT. The proportion of in-
fections that are cured by 6 months of IPT is estimated.
Assumption 3 (estimated percentage cured, estimated per-
centage protection). Six months of IPT can cure <100%
of infections, with <100% protection against reinfection
during IPT. Both the proportion of infections that are
cured by 6 months of IPT and protection against reinfec-
tion during IPT are estimated.
For each assumption, we ﬁtted by maximum likelihood
cluster-speciﬁc model predictions of the measured incidence
and prevalence of culture-positive tuberculosis during the
primary outcome measurement period and ﬁnal prevalence
survey, respectively (each from 1 time point) for the age
groups <40 and ≥40 years to observed data, to estimate the
unknown parameters (Web Appendix 3;Web Table 8). These
were used to calculate the best-ﬁtting impact, generating a
95% conﬁdence interval using bootstrapping (WebAppendix
3; Web Figures 8 and 9). This ﬁtting used base-case model
parameter values (Table 1), which, for IPT assumption 1, fa-
cilitate exploring whether factors (IPT coverage, treatment,
etc.) explained the lack of detectable population-level impact.
By using model predictions of incidence and prevalence, the
ﬁtting accounts for correlations between the two quantities.
The sensitivity of the best-ﬁtting impact to alternative val-
ues for the annual risk of infection (10% and 30% per year),
HIV prevalence (20%, 35%, and 40%), and prevalence of ac-
tive tuberculosis among newly employed miners was also ex-
plored (differing by 0%, 33%, 66%, and 100% from the ﬁnal
prevalence survey estimates), keeping all other parameters at
base-case values. Web Appendix 3 provides further details.
The parameters estimated through ﬁtting account for the
uncertainty in the intervention’s observed impact, assuming
that all remaining parameters equaled the values measured in
the process data. To account for uncertainty in the latter, we
used “Bayesian melding” (15–18) to identify the credible
range of key IPT-related parameters. The likelihood of the
observed incidence and prevalence was computed for 2.28
million sets of randomly drawn parameter values, comprising
40 parameters each (Table 1). Using fewer (1.5 million) param-
eter combinations gave similar outcomes. We then resampled
20,000 parameter sets by using the likelihood of the observed
incidence as the weight and calculated the median and 95%
credible range of the IPT-related parameters and the impact
on the incidence and prevalence. Taking additional samples
did not affect the outcomes. The resampling was repeated by
using the likelihood of the prevalence data as the weight.
In subsequent analyses, the base-case parameters, IPT as-
sumptions, and best-ﬁtting parameters leading to the smallest
impact on the measured incidence and prevalence were used.
Objective 2. The best-achievable impact of Thibela TB.
The best-achievable impact of Thibela TB was estimated
by running the model for base-case and best-ﬁtting parameter
values (from objective 1), after changing implementation
variables (initial loss to follow-up and treatment delay fol-
lowing diagnosis, the sensitivity of screening on enrollment,
and IPT uptake and retention) both individually and concur-
rently to optimized levels (Table 2; Web Appendix 4; Web
Tables 9 and 10).
Objective 3. What might control tuberculosis in gold mines?
Interventions implemented individually. Using the model
calibrated to trial results in objective 1, we simulated the im-
pact of additional interventions, besides reduced initial loss to
follow-up and treatment delay (Table 2). These were as fol-
lows: 1) preventive treatment with isoniazid or a curative reg-
imen; 2) ART scale-up; and 3) improved diagnosis by using
Xpert MTB/RIF introduced into the intervention clusters in
2008 (ﬁrst year of the primary measurement period) in the
model, after removing the Thibela TB intervention (Web Ap-
pendix 4; Web Table 10). The annual true culture-positive
tuberculosis incidence (measurable by detecting all cases im-
mediately after disease onset), averaged across the interven-
tion clusters, was calculated until 2017 and compared with
that in the control condition.
The population attributable fraction for silicosis. The
population attributable fraction for silicosis was calculated
to determine potential reductions in true tuberculosis inci-
dence achievable by dust control (19) (Web Appendix 4;
Web Table 11).
The combined impact of 4 multiple interventions. The
combined impact of the following 4 multiple interventions
was estimated by using the model (Table 2):
1. Reduced initial loss to follow-up and treatment delay.
2. Xpert MTB/RIF is the ﬁrst test used at routine medical ex-
aminations for new mining employees and diagnosis.
3. Increased ART coverage, reaching 80% of all HIV-positive
workers by 2009.
4. ART recipients receive IPT continuously.
RESULTS
Objective 1. Exploring factors contributing to the
lack of population-level impact
After incorporating all known data and factors (migration,
ART uptake, silicosis, IPT uptake and retention, treatment
delay, and initial loss to follow-up) and ﬁtting to the observed
outcomes, we found that the model based on IPT assump-
tions 1 (100% cure, 100% protection) ﬁtted the data poorly.
The best-ﬁtting impact of 24.5% (95% CI: 24.2, 25.0) and
17.8% (95% CI: 15.0, 21.0) on the measured incidence for
IPT assumptions 1 and 2, respectively, exceeded that ob-
served but was inside the latter’s 95% conﬁdence interval
(−48, 27) (Figure 4A). Findings for the best-ﬁtting impact
on prevalence were similar. Web Appendix 5, Web Table 12,
and Web Figures 10–14 include further details.
IPT assumption 3 (estimated percentage cured, estimated per-
centage protected) led to the lowest overall impact of 11.2%
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Table 2. Summary of Changes Made to Individual Factors When Estimating the Maximum Achievable Impact of Thibela TB (Objective 2) or What
Might Control Tuberculosis in the Mines (Objective 3)
Factor Value Based on Empirical Data
From the Trial
Explored Value
Objective 2 (The Best Achievable
Impact in Thibela TB)
Objective 3 (What Might Control TB
in Gold Mines)
Initial loss to
follow-up
sm+: 25%–40%; sm−: 50%–60% 5% As for objective 2
Average treatment
delay after
detection
sm−: 7–9 weeks (45%–60% within
3 months); sm+: 3–4 weeks
(55%–75% within 1 month)
sm−: 3 weeks (90% within
3 months);
Without Xpert MTB/RIF: as for objective 2; with
Xpert MTB/RIF: 2 weeks for both sm+ and
sm−a,bsm+: 2 weeks (90% within
1 month)a,b
Sensitivity of case
screening on
enrollment into
Thibela TB
50% on average ∼100% (potentially achievable if
culture had been used instead
of smear for suspected TB at
the initial screen)
Not applicable
Preventive
treatment
9 months of IPT is provided for all
individuals at observed levels of
coverage and retention (refer to
Web Figure 1 for the proportion
on IPT achieved during the trial).
9 months of IPT is provided for all
individuals, but 1) uptake and/
or 2) retention equals that in the
best-performing cluster in
Thibela TB. With both
optimized, the proportion on
IPT equals that for cluster 7
(70%–80% of the cluster on IPT
at the peak)c
1) Mass community-wide IPT: 9 months of IPT
is provided for all individuals, with coverage
and retention equaling those in the best-
performing cluster (cluster 7) in Thibela TB.
The proportion of infections that are cured
and the protection provided against
reinfection equal those associated with the
greatest impact in objective 1.
2) Continuous IPT for 50% of the population:
9months of IPT is provided as directly above,
with those still taking IPT 9 months after
starting it (∼50% of the population)
continuing to do so, along with 50% of new
mining employeesa
3) 3-month curing regimen: isoniazid and
rifapentine, similar to that described in
the report by Sterling et al. (47) provided
as directly above. Infections are considered
to be cured after completing the regimen,
and recipients experience 100%
protection against reinfection during the
regimen.a
ART coverage 0% in 2003, increasing to ∼70%
among those with a CD4 count of
<200 cells/mL by 2013d,e
No change Increased from the levels in 2008 to reach 80%
by 2009 among those eligible, defined for
3 criteria: those with a CD4 count of
<350 cells/mL, <500 cells/mL, or all HIV-
positivesa
TB disease
detection and
diagnosis
All miners at their routine medical
examination (approximately
every 1.5 years) and new mining
employees are screened using
radiographs. Those with
suspected TB are investigated by
using either culture (company A)
or with culture for those with
previous TB and smear otherwise
(companies B/C).Cases
presenting passively are
investigated with culture
(company A) or with smear and/
or radiological/clinical signs
(companies B/C).
No change Sensitivity of Xpert MTB/RIF is assumed to be
55% and 97% for sm− and sm+ TB disease,
respectively; refer to the report by Dorman
et al. (48).
1) Screen with radiographs and diagnose
suspects with Xpert MTB/RIF. Radiographs
are used to screen miners presenting at the
routine medical examination or when joining
the workforce, in the same way that they are
used in current practice (and therefore with
the same sensitivity), but Xpert MTB/RIF is
used to diagnose suspected TB both in the
routine medical examination and on passive
presentation.a,f
2) Screen and diagnosewith Xpert MTB/RIF.
Xpert MTB/RIF is used to screen and
diagnose cases in the routine medical
examination, when joining the workforce,
and for miners who self-present.a,f
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IPT, isoniazid preventive therapy; sm− and sm+, smear-negative
and smear-positive, respectively; TB, tuberculosis.
a Web Appendix 4.
b Web Table 9.
c Web Figure 1.
d Web Appendix 2.
e Web Figure 4.
f Web Table 10.
626 Vynnycky et al.
Am J Epidemiol. 2015;181(8):619–632
D
ow
nloaded from
 https://academ
ic.oup.com
/aje/article-abstract/181/8/619/84973 by Acquisitions user on 02 August 2019
(95% CI: 10.7, 15.6) and 7.3% (95% CI: 6.7, 13.9) on the mea-
sured incidence and prevalence, respectively (Figure 4). For
HIV-positive individuals, IPT cured a small percentage of infec-
tions, that is, 0.01% (95%CI: 0.00, 0.53) and provided little pro-
tection against reinfection, that is, 0.12% (95% CI: 0.00, 0.55).
These estimates are implicitly averaged across CD4 strata. Insuf-
ﬁcient power existed to estimate these values for HIV-negative
individuals (Web Appendix 5; Web Table 12).
The best-ﬁtting impact for each model remained similar for
each assumed value for the annual risk of infection, HIV
prevalence, and tuberculosis prevalence among newly em-
ployed miners (Web Appendix 5; Web Figure 15).
These ﬁndings were consistent across parameter values that
were resampled using the likelihood of the incidence as the
weight (Figure 5). The percentage of infections that were
cured by 6 months of IPT was low for HIV-positive miners
(median, 13.5%; 95% credible range, 0.7−66) but in a wide
range for those who were HIV-negative (median, 55%; 95%
credible range, 10–96), as was the IPT-derived protection
against reinfection (median, 25%; 95% credible range, 0.4–
75 for HIV-positive miners). The impact on the measured in-
cidence and prevalence associated with these values was 14%
(95% credible range, 11–17) and 9% (95% credible range, 6–
12), respectively. Using the likelihood of the prevalence data
as the weight gave similar ﬁndings (Web Figure 16).
Objective 2. The best-achievable impact of Thibela TB
The additional impact on tuberculosis incidence measured
during the primary measurement period achievable by chang-
ing individual factors (treatment delay, sensitivity of case
screening, or IPT uptake or retention) was 1%–8% for each
IPT model (Web Figures 17 and 18). Additional 21% and 13%
reductions were predicted for IPT assumptions 1 (100% cure,
100% protection) and 3 (estimated percentage cure, estimated
percentage protection), respectively, with all factors at their op-
timal achievable level. These reductions were temporary. The
predicted measured incidence 5 years after introducing IPT dif-
fered by 5%–15% from the base-case value (Web Figure 19).
Additional reductions were predicted only after reducing popu-
lation mobility to unattainable levels (Web Figure 19). These
reductions were relatively insensitive to the assumed annual
risk of infection, HIV prevalence, and tuberculosis prevalence
among new employees (Web Figure 20).
Objective 3. What might control tuberculosis in
gold mines?
Without additional interventions, the average predicted true
tuberculosis incidence declined from about 5,000 to 4,000/
100,000/year during 2008–2017 (Figure 6), reﬂecting increas-
ing ART uptake in some clusters. Reducing initial loss to
follow-up to 5% and the average treatment delay to 3 and 2
weeks for all smear-negative and smear-positive cases, respec-
tively, detected by the health services (Table 2) reduced this fur-
ther to 3,000/100,000/year by 2017 (Figure 6A). Implementing
interventions individually resulted in <30% reductions in the
predicted long-term true incidence compared with that without
interventions (Figure 6). The greatest reductions resulted from
scaling-up ART to levels in Table 2, providing continuous
IPTor tuberculosis screening (routinemedical examination, new
employees, and self-presenting miners) with Xpert MTB/RIF.
Introducing 9months of IPTor a 3-month curative regimen at
the highest achievable coverage, with reduced treatment delay
and initial loss to follow-up, led to initial reductions in the pre-
dicted true incidence, which reversed, eventually matching that
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Figure 4. Summary of the best-fitting impact on the weekly measured tuberculosis disease incidence rate (per 100,000 person-years) during the
Thibela TB randomized controlled trial among South African gold miners, 2006–2011. The incidence rate is defined as the incidence that would be
observed if it were measured weekly. A) Model predictions obtained by assuming that IPT fully cures all infections and protects against reinfection
(IPT assumption 1: 100% cure, 100% protection); B) model is permitted to estimate that 6 months of IPT does not cure all infections and also does
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predicted without preventive treatment (Figure 6A). The reduc-
tion persisted if 50% of miners took IPT continuously, with the
true incidence reaching about 40% of that predicted by 2017 by
reducing treatment delay and initial loss to follow-up.
Scaling upART provision to 80% of HIV-positives by 2009
also led to large (30%), sustained reductions in the predicted
true incidence (Figure 6B), resembling the impact of providing
ART to 80% of those with CD4 counts of <500 cells/mL.
As regards interventions relating to detection and diagno-
sis (Table 2), the use of radiographs to screen new employees
and those attending routine medical examinations (current
practice) and Xpert MTB/RIF to conﬁrm suspected tubercu-
losis (option 1) was predicted to scarcely affect true tubercu-
losis incidence, after reducing initial loss to follow-up and
treatment delay (Figure 6C). Replacing radiographs with
Xpert MTB/RIF as the ﬁrst test for new employees, routine
medical examinations and investigation of self-reported
symptoms (option 2) led to a 30% reduction in the true inci-
dence predicted by 2017, compared with that without using
Xpert MTB/RIF.
For all assumptions about HIV prevalence, <10% of true
tuberculosis incidence was attributed to silicosis (Web Fig-
ure 21), much less than that attributed to HIV (60%–70%).
The greatest reductions in true incidence were predicted for
combined multiple interventions (Figure 6D). Increasing ART
coverage to 80% ofHIV-positives by 2009, reducing treatment
delay, and screening with Xpert MTB/RIF led to a 60% reduc-
tion predicted by 2017, compared with that without additional
interventions. If IPT were also to be provided to ART recipi-
ents, the reduction reached 70% and 80% in the overall popu-
lation and those HIV-positive, respectively (Web Figure 22).
DISCUSSION
Our analysis, supported by ﬁndings from ﬁtting the base-
case model to trial data and sampling >2 million parameter
combinations, suggests that a possible explanation for the
lack of a detectable population-level impact in Thibela TB
is that IPT cured a small proportion of latent infections, at
least among HIV-positive miners. Other contributing factors
include suboptimal IPT uptake and retention. The optimized
intervention increased impact by only 10%. Tuberculosis
control in gold mines requires implementing interventions
simultaneously, including health systems improvements re-
ducing treatment delay and initial loss to follow-up, improved
diagnostics, scaling-up ART, and providing IPT continu-
ously to HIV-positive workers.
The model used was complex, which is justiﬁable, given
multiple competing hypotheses for why no population-level
impact was detected, including suboptimal IPT uptake and re-
tention, as well as high population mobility. To robustly ad-
dress why this occurred, we found that the model needed to
include all known factors at levels supported by the trial’s pro-
cess data. These factors did not fully explain the lack of detect-
able population-level impact because, after incorporation of
both the known data and the assumption that IPT cured all
infections, the model ﬁtted the data poorly. The population-
level impact might have changed little evenwith optimized im-
plementation. A simpler model than that used here would have
excluded some factors and could not determine their contribu-
tion to the trial’s lack of detectable population-level impact.
Our model did not include drug resistance, which probably
contributed little to the study’s population-level impact, given
the low (<15%) prevalence of isoniazid resistance (2) and no
evidence that IPT’s effectiveness is reduced at such levels (20,
21). We note that our Bayesian melding analyses suggest that
14% of infections were cured, which would have increased to
just 16% (0.14/0.85) by including drug resistance in themodel.
Our ﬁnding that isoniazid may not cure latent infections is
consistent with observations that it targets actively replicating
rather than dormant bacilli (6). We could not reliably estimate
its outcome for HIV-negative workers, given their small
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contribution to disease incidence and the lack of HIV-speciﬁc
tuberculosis incidence data. Differences by HIV status probably
exist, given the different incidence trends reported between
HIV-positive and HIV-negative individuals after stopping
IPT (3, 11–14, 22). The lack of detectable impact of preventive
therapy elsewhere (23, 24) suggests that ubiquitous silica dust
exposure in gold mines, impairing macrophage function (25),
may have affected the ability to sterilize latent infections or pre-
vent reinfections, even in HIV-negative miners.
Although improved implementation, including increased
IPT uptake and retention, might have helped to increase the
impact on tuberculosis incidence, this probably would have
been short lived (Web Figure 19), even with a 3-month cura-
tive regimen (Figure 6A), largely because of employees with
latent infection or tuberculosis disease joining the workforce
and, potentially, developing disease and/or transmitting infec-
tion. These factors, the HIV prevalence and IPT coverage/
retention, partly explain the different impact in theAlaskan IPT
trial and Thibela TB. Providing IPT to new gold mining em-
ployees could potentially increase the durability.
The durable impact predicted with providing continuous
IPT (Figure 4) supports recent South African guidelines rec-
ommending ≥36 months of IPT for HIV-positive, tuberculin-
positive people (26).We accounted for theminimal IPT-derived
beneﬁt for tuberculin-negative individuals (13): The assumed
protection was based on all trial participants, irrespective of
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Figure 6. Impact of different interventions implemented individually (A–C) or in combination (D) predicted for the Thibela TB randomized controlled
trial among South African gold miners, 2006–2011. Summary of the predicted impact of different interventions on the number of cases/100,000/year
(the true TB incidence rate), after the treatment delay has been reduced. Each panel shows the impact of reduced treatment delay plus in A) pre-
ventive treatment, with 1) IPT provided community-wide in an initial round for 9 months of IPT, with coverage at the highest levels seen in Thibela,
and 2) IPT provided community-wide in an initial round for 9 months, with coverage at the highest levels seen in Thibela, followed by continuous
community-wide IPT with 50% coverage. This is achieved through keeping those who are still on IPT at the end of the initial round on IPT thereafter
and providing IPT to 50% of new mining employees, and 3) a single round with a 3-month fully curing regimen provided community-wide (without 9
months of IPT), with coverage at the highest levels seen in Thibela. B) Scale-up of ART, with ART coverage increasing to reach 80% in 2009 in the
HIV-positive groups specified in the figure legend; C) improved diagnosis using Xpert MTB/RIF, with 1) radiographs being used to screen at routine
medical examinations and for newly employedminers and Xpert MTB/RIF being used to diagnose peoplewith suspected TB, and 2) Xpert MTB/RIF
being used to screen and diagnose at routine medical examinations for newly employed miners and on passive presentation; D) combined inter-
ventions. Combined impact of introducing reduced treatment delay, screening with Xpert MTB/RIF, ART for 80% of HIV-positive people, and IPT for
those on ART. The shaded areas show the incremental impact of adding each intervention, so that the white area reflects the impact of having all
interventions in place simultaneously. For the scenario involving Xpert MTB/RIF, Xpert MTB/RIF is used in routine medical examinations, for newly
employed miners, and on passive presentation. For both the ART and ART/IPT scenarios, the coverage is increased to reach 80% by 2009. ART,
antiretroviral therapy; HIV+, human immunodeficiency virus–positive; IPT, isoniazid preventive therapy; PT, preventive therapy; TB, tuberculosis.
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tuberculin status (5). However, we have not included immune
function improvements during prolonged ART, which may
help to restore the ability to sterilize latent infections and in-
crease the beneﬁt of providing IPT with ART.
We may have underestimated the impact of improved dust
control because of underascertainment of silicosis. Radiology
has low (∼30%) sensitivity for detecting nodules (27), and
increasing cumulative silica dust exposure increases the risk
of tuberculosis even in miners with normal chest radiographs.
In South Africa, 20%–30% of gold miners who die from any
cause may have histopathological silicosis (28, 29), with 50%
and 30% of HIV-positive and HIV-negative miners, respec-
tively, having active tuberculosis (28).
Several factors, including the sensitivity of existing diagnos-
tics and delays in care-seeking, inﬂuence the impact of im-
proved diagnostics (30). This may be small if Xpert MTB/
RIF is used to diagnose self-reported tuberculosis symptoms
and conﬁrm suspected radiological tuberculosis at routine med-
ical examinations (Figure 6). It increases substantially if it re-
places radiology at routine medical examination, reﬂecting the
relatively high and unusually low sensitivity of Xpert MTB/
RIF and radiological screening, respectively, in gold miners.
Our analyses suggest that tuberculosis incidence in gold
mines may decrease substantially by introducing several in-
terventions simultaneously. Tuberculosis morbidity declined
rapidly during the Alaskan IPT trials, which were accompa-
nied by greatly intensiﬁed case-ﬁnding and treatment (11).
The reductions attributable to any given intervention will be
setting speciﬁc. The predicted impact of reducing treatment
delay could be large in gold mines that have high losses to
treatment following tuberculosis diagnosis and high trans-
mission rates, but minimal elsewhere.
The lack of a detectable impact in Thibela TB strongly sug-
gests that IPT cures a small proportion of latent infections in
gold miners. With optimized IPT uptake and retention, as well
as case-screening and treatment delays, an increased (albeit
nondurable) impact might have been seen. Effective tubercu-
losis control in gold mines and other high incidence settings
requires a combination prevention approach, including health
systems improvements to minimize treatment delay, improved
diagnostics, increased and improved ART coverage, and effec-
tive durable preventive treatment regimens.
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